OppenheimerFunds Inc. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,002,176 shares of the biopharmaceutical company’s stock after buying an additional 2,176 shares during the period. OppenheimerFunds Inc.’s holdings in Halozyme Therapeutics were worth $12,988,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Pictet Asset Management Ltd. purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at about $18,888,000. Senzar Asset Management LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $12,107,000. Artisan Partners Limited Partnership purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at about $13,424,000. Norges Bank purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $10,026,000. Finally, State Street Corp boosted its position in shares of Halozyme Therapeutics by 17.1% in the fourth quarter. State Street Corp now owns 3,819,690 shares of the biopharmaceutical company’s stock valued at $37,742,000 after buying an additional 558,479 shares during the period. Institutional investors own 81.77% of the company’s stock.
Halozyme Therapeutics, Inc. (NASDAQ HALO) traded up 2.61% on Tuesday, reaching $14.54. The company had a trading volume of 299,914 shares. Halozyme Therapeutics, Inc. has a 12 month low of $7.70 and a 12 month high of $15.20. The company’s market capitalization is $1.87 billion. The company’s 50 day moving average price is $13.31 and its 200-day moving average price is $12.64.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.01. The business had revenue of $29.60 million during the quarter, compared to the consensus estimate of $30.79 million. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 86.80%. The firm’s revenue was down 30.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.16) earnings per share. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post ($1.00) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Halozyme Therapeutics, Inc. (HALO) Position Boosted by OppenheimerFunds Inc.” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/2655408/halozyme-therapeutics-inc-halo-position-boosted-by-oppenheimerfunds-inc.html.
HALO has been the topic of a number of recent research reports. Zacks Investment Research upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 24th. Deutsche Bank AG raised their target price on Halozyme Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, March 30th. BMO Capital Markets initiated coverage on Halozyme Therapeutics in a research note on Monday, April 17th. They issued a “market perform” rating and a $14.00 target price on the stock. ValuEngine upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $14.46.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.